BiotechTube

Etoposide + Gemcitabine + Irinotecan + Paclitaxel + Carboplatin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasms, Unknown Primary

Conditions

Neoplasms, Unknown Primary

Trial Timeline

Sep 1, 2003 → Jun 1, 2009

NCT ID
NCT00193596

About Etoposide + Gemcitabine + Irinotecan + Paclitaxel + Carboplatin

Etoposide + Gemcitabine + Irinotecan + Paclitaxel + Carboplatin is a phase 3 stage product being developed by Eli Lilly for Neoplasms, Unknown Primary. The current trial status is completed. This product is registered under clinical trial identifier NCT00193596. Target conditions include Neoplasms, Unknown Primary.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms, Unknown Primary were approved

Approved (20) Terminated (2) Active (0)
✅LenvatinibEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Chlorhydrate de RopivacaineAstraZenecaApproved
✅Sitagliptin + placeboMerckApproved
✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00193596Phase 3Completed

Competing Products

20 competing products in Neoplasms, Unknown Primary

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
AB0024Gilead SciencesPhase 1
29
TTI-237PfizerPhase 1
21
852APfizerPhase 1
29
PemetrexedEli LillyPhase 2
35
IMC-3C5Eli LillyPhase 1
29
LY3295668Eli LillyPhase 1/2
32
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
LY2784544Eli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
29
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
120 mg LY2784544Eli LillyPhase 2
39
LY4337713Eli LillyPhase 1
36
pemetrexed + cisplatinEli LillyPhase 1/2
32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mgVincerx PharmaPhase 1
19
VIP236 (Q3W) + VIP236 (Q2W)Vincerx PharmaPhase 1
19